[HTML][HTML] Optimal dosages and genotypes for edoxaban therapy
K Huynh - Nature Reviews Cardiology, 2015 - nature.com
… of treatment. Notably, the lower bleeding risk associated with edoxaban versus warfarin use
was … responders during the first 90 days of treatment. These results demonstrate that patients …
was … responders during the first 90 days of treatment. These results demonstrate that patients …
Pharmacogenomics of anticoagulation therapy: the last 10 years
G Ragia, VG Manolopoulos - Pharmacogenomics, 2019 - Taylor & Francis
… and most recently edoxaban have gradually dominated over … was reduced in genotype-guided
warfarin dosing arm that … , both predicting the optimal dosing of COAs and identifying …
warfarin dosing arm that … , both predicting the optimal dosing of COAs and identifying …
Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis
LA Linkins, PT Choi, JD Douketis - Annals of internal medicine, 2003 - acpjournals.org
… , particularly in the subgroup of patients with venous thromboembolism in whom the optimal
duration of anticoagulant therapy is unclear. These patients include those with unprovoked (…
duration of anticoagulant therapy is unclear. These patients include those with unprovoked (…
Genotype‐guided warfarin therapy: Still of only questionable value two decades on
RR Shah - Journal of Clinical Pharmacy and Therapeutics, 2020 - Wiley Online Library
… Expectations that genotype-based warfarin dosing might … supportive of genotyping, the
effect size (benefit) is at best only … benefit with edoxaban, a novel NOAC, rather than warfarin.…
effect size (benefit) is at best only … benefit with edoxaban, a novel NOAC, rather than warfarin.…
Anticoagulant therapy for women: implications for menstruation, pregnancy, and lactation
E DeLoughery, BS Bannow - Hematology, 2022 - ashpublications.org
… edoxaban have both demonstrated a higher risk of uterine bleeding compared with warfarin.
… (12 hours for prophylactic dosing) to ensure neutralization of an anticoagulant effect prior to …
… (12 hours for prophylactic dosing) to ensure neutralization of an anticoagulant effect prior to …
[HTML][HTML] Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants
N Cullell, C Carrera, E Muiño, N Torres, J Krupinski… - Oncotarget, 2018 - ncbi.nlm.nih.gov
… whether genotype can refine maintenance dose of warfarin after some days of therapy. One
… score ≥ 3, both edoxaban doses had positive NCB compared to warfarin, in patients with …
… score ≥ 3, both edoxaban doses had positive NCB compared to warfarin, in patients with …
Impact of Factor VII Polymorphism on Responsiveness to Warfarin Anticoagulant Therapy
OH Shaaban, HAE Serogy, MK Zahra… - Journal of Advances …, 2023 - archive.jibiology.com
… Patients with the FVII -401GG genotype receive significantly more warfarin on a daily …
genotype [13]. While the FVII -402 AA genotype is associated with higher daily doses of warfarin …
genotype [13]. While the FVII -402 AA genotype is associated with higher daily doses of warfarin …
Pharmacodynamics and pharmacokinetics of stroke therapy
… from the knowledge of CYP2C19 genotype, as presence of the … Optimal duration of oral
anticoagulation with dabigatran in … Edoxaban should not be given with creatine clearances under …
anticoagulation with dabigatran in … Edoxaban should not be given with creatine clearances under …
[图书][B] … Pulmonary Embolism Transcatheter Interventions, An Issue of Interventional Cardiology Clinics: Antiplatelet and Anticoagulation Therapy in Cardiovascular and …
LO Paz - 2024 - books.google.com
… Drs Lina Manzi and Giuseppe Gargiulo review the best … potent P2Y12 inhibitor at conventional
doses to either clopidogrel or … selection of antiplatelet therapy by means of genotyping or …
doses to either clopidogrel or … selection of antiplatelet therapy by means of genotyping or …
Factors affecting the safe use of oral anticoagulants
SAO Abohelaika - 2017 - theses.ncl.ac.uk
… is related to VKORC1 genotype. Based upon … warfarin therapy with the VKORC1(-1639)GG
polymorphism could have poorer anticoagulation control than those with GA or AA genotypes …
polymorphism could have poorer anticoagulation control than those with GA or AA genotypes …